Forte Biosciences

FBRX

Market cap $153M

Overview Fund Activity

12.33 USD

+0.85

7.4%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

12.33

0.00

0%

1 day

7.4%

5 days

12.09%

1 month

3.53%

3 months

-9.34%

6 months

123.37%

Year to date

-51.21%

1 year

69.83%

5 years

-98.87%

10 years

-99.74%

About: Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).

Employees: 17

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

275% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 4

223% more capital invested

Capital invested by funds: $39.3M [Q1] → $127M (+$87.7M) [Q2]

100% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

70.22% more ownership

Funds ownership: 78.79% [Q1] → 149.01% (+70.22%) [Q2]

14% more funds holding

Funds holding: 29 [Q1] → 33 (+4) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$61

395% upside

Avg. target

$68

452% upside

High target

$75

508% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Guggenheim Yatin Suneja	$75	Buy Initiated	18 Aug 2025
Chardan Capital Daniil Gataulin	$61	Buy Maintained	15 Aug 2025

See Analyst Rankings

Financial journalist opinion

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation “FB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study - Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital” at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland).

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Forte Biosciences, Inc. Announces Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its second quarter 2025 financial results and provided a business update. “I am deeply appreciative of the Forte team's incredible accomplishments in initiating 3 clinical trials for FB102 with data readouts shortly.” said Forte Biosciences CEO Paul Wagner, PhD. “We have begun dosing subjects in th.

Forte Biosciences, Inc. Announces Results and Provides Update

Forte Biosciences Announces Pricing of $75 Million Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which rep.

Forte Biosciences Announces Pricing of $75 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares.

Forte Biosciences Announces Proposed Public Offering

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be.

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Forte Biosciences, Inc. Announces Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2025 financial results and provided a clinical update. “We are looking forward to reading out the topline data from the FB102 celiac disease trial this quarter. FB102 continues to be well-tolerated and there have been no dropouts to date. Additionally, we have now dosed the first.

Forte Biosciences, Inc. Announces Results and Provides Update

Zacks Investment Research

All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy

Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced full year 2024 results and provides a clinical update. “2024 was a very productive year with significant progress on the development of FB102, including the completion of the healthy volunteer study and the initiation of celiac patient trial,” said Forte Biosciences CEO Paul Wagner, Ph.D. “The celi.

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte's CEO, Paul Wagner, PhD will be presenting at the Guggenheim SMID Cap Biotech Conference at 1:30 PM ET on February 6th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 3rd at 10:30 AM ET, Dr. Wagner will be pr.

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Zacks Investment Research

Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why

Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why

See News Rankings

Charts implemented using Lightweight Charts™